Context Therapeutics (NASDAQ:CNTX) Issues Earnings Results, Beats Expectations By $0.01 EPS

Context Therapeutics (NASDAQ:CNTX) posted its quarterly earnings data on Thursday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01, reports.

Context Therapeutics Stock Up 0.2 %

Shares of CNTX stock opened at $0.77 on Friday. The firm has a market cap of $57.88 million, a price-to-earnings ratio of -0.85 and a beta of 2.06. The company’s 50 day moving average is $0.85 and its 200 day moving average is $1.44. Context Therapeutics has a 52-week low of $0.64 and a 52-week high of $2.75.

Analyst Ratings Changes

CNTX has been the topic of a number of recent analyst reports. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Friday. JMP Securities initiated coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 target price on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Friday. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $6.17.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.